GSK plc Sponsored ADR (GSK)
GSK forecast upgrade fails to impress the market
GSK PLC (LSE:GSK, NYSE:GSK) has raised its annual earnings and sales forecasts after a strong second-quarter performance driven by cancer and HIV treatments. However, the performance singularly failed to impress the market still worried about the potential financial whack the drug giant might take from ongoing Zantac litigation as the shares opened 1.3% lower.
GSK raises annual profit and sales forecast after second quarter beat
British drugmaker GSK raised its annual earnings and sales forecasts on Wednesday and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.
GSK reaches confidential settlement in Illinois
GSK PLC (LSE:GSK, NYSE:GSK) said it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court, which is part of the drug giant's long-running Zantac litigation. The UK pharma giant stressed it did not admit any liability in this settlement.
GSK's vaccine receives positive European Medicines Agency opinion
GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to extend its use to adults aged 50-59 who are at increased risk of RSV. If approved, it will be the first RSV vaccine for this age group in the EU.
GSK settles another Illinois Zantac lawsuit
British drugmaker GSK on Monday said it has agreed to confidentially settle a lawsuit in Illinois alleging its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.
Here's Why GSK (GSK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59
The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSK (GSK) Earnings Expected to Grow: Should You Buy?
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
Is GSK a Top-Value Stock Right Now?
GSK stock has a long track record of lagging behind the broader markets. Under CEO Emma Walmsley, the drugmaker has made significant strides toward improving its core-value proposition to shareholders.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
